[HTML][HTML] Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis

WR Swindell, X Xing, PE Stuart, CS Chen, A Aphale… - PloS one, 2012 - journals.plos.org
WR Swindell, X Xing, PE Stuart, CS Chen, A Aphale, RP Nair, JJ Voorhees, JT Elder
PloS one, 2012journals.plos.org
The clinical features of psoriasis, characterized by sharply demarcated scaly erythematous
plaques, are typically so distinctive that a diagnosis can easily be made on these grounds
alone. However, there is great variability in treatment response between individual patients,
and this may reflect heterogeneity of inflammatory networks driving the disease. In this study,
whole-genome transcriptional profiling was used to characterize inflammatory and cytokine
networks in 62 lesional skin samples obtained from patients with stable chronic plaque …
The clinical features of psoriasis, characterized by sharply demarcated scaly erythematous plaques, are typically so distinctive that a diagnosis can easily be made on these grounds alone. However, there is great variability in treatment response between individual patients, and this may reflect heterogeneity of inflammatory networks driving the disease. In this study, whole-genome transcriptional profiling was used to characterize inflammatory and cytokine networks in 62 lesional skin samples obtained from patients with stable chronic plaque psoriasis. We were able to stratify lesions according to their inflammatory gene expression signatures, identifying those associated with strong (37% of patients), moderate (39%) and weak inflammatory infiltrates (24%). Additionally, we identified differences in cytokine signatures with heightened cytokine-response patterns in one sub-group of lesions (IL-13-strong; 50%) and attenuation of these patterns in a second sub-group (IL-13-weak; 50%). These sub-groups correlated with the composition of the inflammatory infiltrate, but were only weakly associated with increased risk allele frequency at some psoriasis susceptibility loci (e.g., REL, TRAF3IP2 and NOS2). Our findings highlight variable points in the inflammatory and cytokine networks known to drive chronic plaque psoriasis. Such heterogeneous aspects may shape clinical course and treatment responses, and can provide avenues for development of personalized treatments.
PLOS